Myriad Study Shows NGS Testing for Hereditary Breast Cancer IDs Variants Outside of BRCA1 and BRCA2 | GenomeWeb

NEW YORK (GenomeWeb) – A recent study by Myriad Genetic Laboratories adds to a growing body of evidence that shows that gene panels can catch variants outside of BRCA1 and BRCA2 in breast cancer patients referred for genetic testing, although there are still unanswered questions about appropriate clinical implementation of such panels.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.